deltatrials
Active Not Recruiting PHASE2/PHASE3 INTERVENTIONAL 6-arm NCT04871282

A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Sponsor: Immunome, Inc.

Conditions Desmoid Desmoid Tumor
Interventions AL102 Placebo
Updated 26 times since 2021 Last updated: Feb 3, 2026 Started: Mar 30, 2021 Primary completion: Dec 3, 2025 Completion: Oct 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04871282, this PHASE2/PHASE3 trial focuses on Desmoid and Desmoid Tumor and remains ongoing. Sponsored by Immunome, Inc., it has been updated 26 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Jul 2025 · 7 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

26 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2/PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  3. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  4. Dec 2024 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  5. Oct 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

▶ Show 21 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE2_PHASE3

  6. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE2_PHASE3

  7. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2_PHASE3

  9. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2_PHASE3

  10. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2_PHASE3

  11. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2_PHASE3

  12. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2_PHASE3

  13. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE2_PHASE3

  14. Jul 2022 — Dec 2022 [monthly]

    Recruiting PHASE2_PHASE3

  15. Mar 2022 — Jul 2022 [monthly]

    Recruiting PHASE2_PHASE3

  16. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2_PHASE3

  17. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2_PHASE3

  18. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2_PHASE3

  19. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2_PHASE3

  20. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2_PHASE3

  21. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immunome, Inc.
Data source: Immunome, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ann Arbor, United States , Ashkelon, Israel , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Boston, United States , Cambridge, United Kingdom , Camperdown, Australia , Charlotte, United States and 37 more locations